• Cancer Stocks: 2 to Buy, 1 to Avoid
    Motley Fool7 days ago

    Cancer Stocks: 2 to Buy, 1 to Avoid

    Here's why you may want to add Bellicum Pharmaceuticals and Exelixis to your portfolio but avoid Ariad Pharmaceuticals.

  • American City Business Journals9 days ago

    Exit of Biogen CEO George Scangos could be big for Bay Area biotechs

    George Scangos, the CEO of Biogen Inc. for the past six years, will step down from his post to return to the West Coast and spend time with his family. The news is big for Biogen (BIIB), which Scangos led through a turnaround from South San Francisco's Exelixis Inc. (EXEL), but it may be even bigger for Bay Area biotech companies. Biogen reported the news of Scangos' departure Thursday morning along with its second-quarter earnings, which beat most analyst expectations with $2.9 billion in revenue for the three months that ended in June.